文献速递泌尿生殖介入MRUS

MRI引导的微超声引导经会阴局灶激光消融治疗局限性前列腺癌:1年随访研究

MRI-directed Micro-US-guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study.
PubMed 文献 · Radiology · 2024-01-01

这项前瞻性单中心观察性研究纳入55例局限性低危或中危前列腺癌患者(58个PI-RADS≥3病灶,≤20mm),行MRI引导的微超声经会阴局灶激光消融。微超声显示91%肿瘤,多光纤消融体积大于单光纤;12个月活检35个治疗肿瘤中17个复发(49%),多光纤复发率18%;勃起功能评分下降、排尿功能稳定,发生1例直肠前列腺瘘需手术。

要点

  • 微超声可显示91%(53/58)的PI-RADS≥3肿瘤,作为MRI融合引导的补充。
  • 多光纤消融体积中位15mL,大于单光纤的4.5mL(P<.001)。
  • 12个月活检35个治疗肿瘤中17个复发(49%),多光纤复发率18%。

核心结论

  • 多光纤微超声引导局灶激光消融安全可行,1年随访复发率为18%。

研究设计与样本

  • 前瞻性单中心观察性研究,2020年7月至2023年6月,55例男性患者共58个PI-RADS≥3病灶(≤20mm),行1064nm局灶激光消融,MRI勾画图像融合引导,12个月随访33例。

关键影像表现/征象

  • 微超声成功显示58个肿瘤中的53个(91%)。
  • 多光纤消融体积中位15mL(IQR 8-22mL),单光纤中位4.5mL(IQR 2.8-9.2mL),P<.001。

诊断标准与关键数值

  • 纳入标准为局限性低危或中危前列腺癌、PI-RADS≥3且病灶≤20mm。
  • 58个病灶中43个(74%)Gleason评分3+4,10个(17%)Gleason评分3+3。
  • 12个月活检35个治疗肿瘤中17个复发(49%),其中13个野内复发、4个野外复发。
  • 野内复发:单光纤18例中10例(56%),多光纤17例中3例(18%)。

临床应用与阅片要点

  • 微超声可用于显示MRI所见的PI-RADS≥3病灶,58个中显示53个(91%)。
  • 单光纤与多光纤消融体积不同:多光纤中位15mL vs 单光纤4.5mL(P<.001)。
  • 12个月勃起功能评分较基线下降(中位IIEF 19 vs 21,P<.001),排尿功能稳定(中位IPSS 2 vs 6,P=.72)。
  • 发生1例直肠前列腺瘘,需手术治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background MRI-guided focal laser ablation (FLA) is a promising treatment in localized prostate cancer (PCa). MRI-guided micro-US FLA shows potential for outpatient use, but its clinical application remains unexplored. Purpose To evaluate the safety, feasibility, and 12-month functional and oncologic outcomes of MRI-guided micro-US transperineal FLA in localized PCa and to assess the accuracy of micro-US in showing lesions depicted at MRI with Prostate Imaging Reporting and Data System (PI-RADS) score of 3 or higher. Materials and Methods This prospective, single-center observational study (July 2020 to June 2023) included participants with localized low- or intermediate-risk PCa and PI-RADS 3 or higher lesions (≤20 mm). Single- or multifiber FLA was performed at 1064 nm, guided by MRI-delineated image fusion. At 12 months, recurrence rates, complications, erectile function scores, and urinary symptom scores were assessed. Mann-Whitney U and Wilcoxon tests were used for comparisons. Results Fifty-five male participants (median age, 70 years; IQR, 62-74 years) with 58 lesions that were PI-RADS 3 or higher underwent transperineal FLA, with a 12-month follow-up for 33 participants. The median prostate-specific antigen level was 7.0 ng/mL (IQR, 5.6-9.0 ng/mL), 43 of 58 lesions (74%) had a Gleason score of 3 + 4, and 10 of 58 lesions (17%) had a Gleason score of 3 + 3. Single-fiber and multifiber FLA were used to treat 21 of 58 (36%) and 37 of 58 (64%) tumors, respectively. At micro-US, 53 of 58 (91%) tumors were successfully visualized. Multifiber FLA produced larger ablation volumes than did single-fiber treatment (median, 15 mL [IQR, 8-22 mL] vs 4.5 mL [IQR, 2.8-9.2 mL]; P < .001). At 12 months, biopsies in 35 treated tumors showed 17 recurrences (49%), including 13 in-field and four out-of-field recurrences. In-field recurrences occurred in 10 of 18 (56%) single-fiber and three of 17 (18%) multifiber cases. At 12 months, erectile function scores decreased compared with baseline (median International Index of Erectile Function score, 19 [IQR, 12-24] vs 21 [IQR, 15-24]; P < .001), whereas urinary function remained stable (median International Prostatic Symptom Score, 2 [IQR, 2-9] vs 6 [IQR, 3-11]; P = .72). One rectoprostatic fistula developed and required surgery. Conclusion Multifiber micro-US-guided FLA was safe and feasible, with 18% recurrence at 1-year follow-up. Clinical trial registration no. NCT05163197 © RSNA, 2024 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Cornud F, de Bie K, van Riel L, et al. MRI-directed Micro-US-guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study. Radiology. 2024. PMID: 39718499. doi:10.1148/radiol.233371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。